Our findings provide genetic evidence supporting the efficacy and safety of LPL pathway activation therapies for the prevention of CAD and T2D, alone or in combination with statins or PCSK9 inhibitors. This evidence concerns the gene PCSK9 and type 2 diabetes mellitus.